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anastrozole was compared with tamoxifen, anastrozole was more effective and costly 
than tamoxifen costing additional KRW 22,461,689 per QALY. Letrozole showed 
similar incremental cost of KRW 21,004,142 per QALY. In the node negative group, 
anastrozole was the most cost-effective with incremental cost of KRW 19,717,770 per 
QALY, while letrozole was the most cost-effective with incremental cost of KRW 
8,150,512 per QALY in node positive group. Sensitive analysis showed that these 
results were robust. CONCLUSIONS: Subgroup analysis clearly demonstrated which 
treatment was superior among aromatase inhibitors. Such a demonstration was not 
conﬁ rmative in the cases of overall population. The implication of this study is that 
the decision maker should be careful when generalizing the cost-effectiveness results. 
The stratiﬁ ed analysis in this context may help reach a reasonable decision on resource 
allocation. 
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OBJECTIVES: The objective of the study was to examine the direct medical cost of 
XELOX (capecitabine plus oxaliplatin) compared to FOLFOX (ﬂ uorouracil/leucovo-
rin plus oxaliplatin) for the treatment of advanced gastric cancer in China. METHODS: 
Since the equal efﬁ cacy was already demonstrated by the published literature and local 
clinical guideline, cost minimization analysis was performed to compare the direct 
medical costs of XELOX and FOLFOX for the treatment of advanced gastric cancer. 
The direct medical costs were associated with the drug costs, drug administration 
costs, hospitalization costs and adverse events management costs. The costs were 
calculated based on a questionnaire survey from a clinical expert panel of 20 gastro-
intestinal surgeons and medical oncologists. RESULTS: According to the result of 
clinical expert panel survey, the median treatment duration of XELOX and FOLFOX 
was six cycles and nine cycles, respectively. The drug cost of XELOX regimen was 
CNY 33,948 (US$4992), higher than FOLFOX by CNY 14,160 (US$2082). However, 
the cost increment of XELOX regimen was offset by the higher drug administration 
cost (deviation CNY 9985), hospitalization cost (deviation CNY 4734) and adverse 
events management cost (deviation CNY 1828) of FOLFOX regimen. As a result, 
XELOX showed a signiﬁ cant overall cost savings of CNY 2386 (US$351) compared 
with FOLFOX. CONCLUSIONS: According to the study, XELOX is cost saving in 
comparison with FOLFOX for the treatment of advanced gastric cancer in China, 
especially in the chemotherapy administration and hospitalization utilization. 
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OBJECTIVES: To estimate the clinical and economic effect of Liquid-Based Cytology 
(LBC) compared with Conventional Papanicolaou Smear (CP) screening program in 
Taiwan. METHODS: A decision analytic model was used to simulate the natural 
history of cervical cancer in Taiwan health-care system. This study adopts a Ministry 
of Health perspective in cost-effectiveness analysis to compare a CP strategy every 
year with eight different screening strategies. These strategies comprise three screening 
tools (CP, LBC with Filter Base Technology, and LBC with Cell Enrichment Technol-
ogy), and three screening intervals (annually, every 3 years, and every 5 years). Out-
comes are life expectancy, quality-adjusted life-years (QALYs), lifetime costs, and 
incremental cost-effectiveness ratios (ICER). Future costs and QALYs were discounted 
at an annual rate of 3%. One-way sensitivity analyses are conducted to assess param-
eter uncertainty. RESULTS: Compared with the current screening strategy (an annual 
CP), LBC with Filter Base Technology and LBC with Cell Enrichment Technology 
strategies every 3 or 5 years are less costly while the QALYs lost are trivial. When 
three times GDP per capita is used as the decision threshold, switching cervical cancer 
screening tools from Pap annually to LBC with Filter Base Technology annually 
strategy or LBC with Cell Enrichment Technology annually strategy are cost-effective, 
with ICER equaling NT$233,000 or NT$272,000 per QALY gained, respectively. 
CONCLUSIONS: Results from this study showed that it may be desirable to adopt 
LBC as primary screening tool and may to extend screening interval annually to every 
3 or 5 years in cervical cancer prevention. 
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OBJECTIVES: Sexually-transmitted Human PapillomaVirus (HPV) is the major cause 
of cervical cancer. For its greatest beneﬁ t, HPV vaccine is recommended for young 
girls before there is a possible exposure to HPV through sexual contacts. To assessing 
the potential beneﬁ ts of HPV vaccination program, it is crucial to collect the compre-
hensive information of infectious status and sexual behavior among adolescents. This 
study aims to implement the simulation technique to overcome the information barrier 
in Taiwan. METHODS: A population-based decision analytic model was established 
to simulate the health histories of 15 birth cohorts till they are aged 12 to 26. In the 
starting-point of simulation, these cohorts are aggregated to form a fully representative 
population in 2009. To capture the potential effects of catch-up vaccination programs, 
we computed the initial distribution of health states among each cohort by Markov 
model with cervical cancer natural history in Taiwanese women. We further validated 
the model by comparing the actual epidemiologic data and simulated results. The 
model was applied to estimate the incremental cost-effectiveness ratio (ICER) of 
the different vaccination programs from the perspective of health care. RESULTS: The 
simulated age patterns of HPV prevalence was corresponding to the observed age 
patterns of sexual experience. Based on the model, we found that inclusion of a HPV 
vaccination program for the cohort aged 12 can be considered as cost-effective (ICER 
value 1,010,000 NTD/QALY) comparing with annual Pap smear program only. 
Catch-up vaccination program for the cohorts aged 12–26 can be considered cost-
effective (ICER value 570,000 to 1,300,000 NTD/QALY) comparing with no inter-
vention. Results of sensitivity analysis suggest the robustness of the analysis. 
CONCLUSIONS: We have developed a model incorporating the local health and 
medical conditions. The population-based model is helpful for assessing a complicated 
public policy involved several generations. It provides plentiful information for esti-
mating the beneﬁ ts and budget impact of public policy. 
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OBJECTIVES: Lung cancer has a high mortality and is associated with a substantial 
ﬁ nancial burden. Cost-effectiveness estimated from foreign studies are usually not 
directly comparable between countries without adapting by applying the appropriate 
national value set. This study was performed to evaluate the cost-effectiveness of 
erlotinib versus docetaxel in patients with advanced non small cell lung cancer(NSCLC) 
who have failed previous chemotherapy in Korea. METHODS: A Markov model 
simulated to access the clinical and economic impact of erlotinib or docetaxel over 2 
years from society perspective. Progression free survival(PFS) and overall survival(OS) 
data were derived from clinical trials, and utility/disutility data were collected in 
published study. Life-year gained(LYG) is projected based on clinical outcomes and 
converted to quality-adjusted life-years (QALYs) by utility weight. Both direct medical 
costs (e.g., drugs, visits, monitoring, etc. ) and nonmedical costs were calculated. Costs 
and outcomes were discounted at an annual rate of 5% and incremental cost-effec-
tiveness ratio (ICER) consists of the difference in cost divided by the difference in 
QALYs. We performed sensitivity analysis to evaluate uncertainty in the results. 
RESULTS: After 2 years follow-up, the total costs per patient was lower with 
erlotinib(11,234,900KRW, 1USD = 1156.53KRW as of February 2010) than with 
docetaxel (12,105,719KRW). More QALY per patient would be obtained with erlo-
tinib than with docetaxel (0.268 and 0.213, respectively). Thus, ICER for erlotinib 
compared to Docetaxel is −15,829,756KRW per QALY. The results of the sensitivity 
analysis showed no signiﬁ cant difference. CONCLUSIONS: This study suggests, with 
its underlying assumptions and data, the use of erlotinib as second- or third-line treat-
ment for advanced NSCLC would not only save costs but also improve outcomes 
compared with docetaxel in Korea. 
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BACKGROUND: CML accounts for 15% of adult leukemia, with incidence ~1 per 
100,000. Imatinib mesylate is an oral medication for chronic phase (CP), accelerated 
phase, or blast crisis phase of CML. For CML patients showing resistance to imatinib, 
dose escalation is a treatment option. Nilotinib is a second generation tyrosine kinase 
inhibitor (TKI), rationally designed to preferentially target BCR-ABL, and has dem-
onstrated efﬁ cacy and safety in patients resistant or intolerant to imatinib. OBJEC-
TIVES: To estimate the total treatment costs and quality-adjusted life-years (QALY) 
gained for patients receiving high-dose imatinib (HDI) ≥600 mg/day because of resis-
tance or nilotinib 800 mg/day using a Markov model to project long-term outcome. 
METHODS: Model parameters were obtained from medical records of patients 
treated with HDI in Taiwan, along with published clinical trial data for HDI and 
nilotinib, and local drug and treatment costs. RESULTS: At the end of July, 2008, 45 
patients who have received imatinib ≥600 mg/day were included in the study and their 
charts were reviewed. During the entire treatment period of HDI and nilotinib, anemia 
was the most common treatment-related adverse event (22.2% vs. 15.6%). The model 
projected longer expected life-years gained by patients receiving nilotinib therapy 
(11.72 years vs. 9.31 years), and patients treated with nilotinib are expected to experi-
ence longer QALY than HDI (9.6 years vs. 7.47 years). Estimated cost per QALY was 
1,189,150 (NTD/year) for nilotinib and 1,169,547 (NTD/year) for HDI. CONCLU-
SIONS: Under the assumption of similar drug price for nilotinib and HD imatinib, 
the beneﬁ t of using nilotinib is obvious for the better clinical outcome achieved in 
terms of lower adverse event rate, better QALY, with acceptable economic impact. 
